Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05076513
Other study ID # 2021-13
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date October 29, 2021
Est. completion date February 2025

Study information

Verified date February 2024
Source St. Joseph's Hospital and Medical Center, Phoenix
Contact Phase 0 Navigator
Phone 602-406-8605
Email research@ivybraintumorcenter.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss. The trial will be composed of a Phase 0 component (subdivided into Arm A and B) and a therapeutic expansion phase. Patients with tumors demonstrating a positive PK Response (in Arm A) or a positive PD Response (in Arm B) of the Phase 0 component of the study will graduate to a therapeutic expansion phase that combines therapeutic dosing of niraparib plus standard-of-care fractionated radiotherapy (in Arm A) or niraparib monotherapy (in Arm B) until progression of disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 42
Est. completion date February 2025
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Arm A participants undergoing resection for a suspected newly diagnosed glioblastoma. For Arm B, participants undergoing resection who have had a prior resection of histologically diagnosed WHO grade II-IV glioma with IDH1 or IDH2 mutation and ATRX loss. 2. Arm A participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm. 3. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable). 4. Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness. 5. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures. 6. Age =18 at time of consent 7. Have a performance status (PS) of =2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982) 8. Ability to swallow oral medications. 9. Confirmed negative serum pregnancy test (ß-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause. If the serum pregnancy test is completed > 7 days from Day 1, a urine pregnancy test will be done to confirm a negative result prior to Day 1 dose administration. 10. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to treatment and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration. 11. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 3 months after the end of treatment administration. Avoid sperm donation for duration of the study and for an additional 6 months after the end of treatment administration. 12. Agreement to adhere to Lifestyle Considerations throughout study duration. 13. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade =1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy and Day 1. 14. Females of child-bearing potential must agree not to breastfeed starting at screening, throughout the study period and for 6 months after final study drug administration. 15. Participant has normal blood pressure or adequately treated and controlled hypertension (Defined as systolic BP =140 mmHg and diastolic BP =90 mmHg). 16. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility): - Adequate Bone Marrow Function: - Absolute Neutrophil Count =1,500/mcL - Platelets (at time of surgery) =100,000/mcL - Hemoglobin =9.0 g/dL. Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion. - Adequate Hepatic Function: - Total Bilirubin =1.5 X ULN. Participants with Gilbert's syndrome with a total bilirubin =2.0 times ULN and direct bilirubin within normal limits are permitted. - AST(SGOT) =2.5 X institutional ULN - ALT(SGPT) =2.5 X institutional ULN - Adequate Renal Function: - Estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m2 by Chronic Disease Epidemiology Collaboration (CKD-EPI) equation - INR =1.5 x ULN Exclusion Criteria: 1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise, that cannot be discontinued prior to surgery. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed. 2. Pregnancy or lactation. 3. Known allergic reactions to components of the niraparib tablet, including FD&C Yellow No. 5.. 4. Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1. 5. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis as determined by the investigator. 6. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment. 7. Any of the following cardiovascular criteria: - Current evidence of cardiac ischemia - Current symptomatic pulmonary embolism - Acute myocardial infarction = 6 months prior to Day 1 - Heart failure of New York Heart Association Classification III or IV = 6 months prior to Day 1 (Appendix 13.2) - Grade = 2 ventricular arrhythmia = 6 months prior to Day 1 - Cerebral vascular accident (CVA) or transient ischemic attack (TIA) = 6 months prior to Day 1 8. Participant has myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of MDS/AML. 9. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 10. Prior therapy with PARP inhibitors at a therapeutic dose. 11. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.

Study Design


Intervention

Drug:
Niraparib
In Phase 0, 300mg administered orally QD for 4 days prior to resection. In the Expansion cohort/Maintenance phase, niraparib will be administered as described below: For patients weighing <77 kg (<170 lbs) OR with a platelet count <150,000/mcL, the recommended dosage is 200 mg taken orally once daily. For patients weighing =77 kg (=170 lbs) AND a platelet count =150,000/ mcL, the recommended dosage is 300 mg taken orally once daily.
Radiation:
Radiation therapy
Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.

Locations

Country Name City State
United States St. Joseph's Hospital and Medical Center Phoenix Arizona
United States University of California San Francisco San Francisco California

Sponsors (5)

Lead Sponsor Collaborator
Nader Sanai Barrow Neurological Institute, GlaxoSmithKline, Ivy Brain Tumor Center, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase 0 Arm A: Total and unbound niraparib concentration in enhancing and nonenhancing tissue Tumor to plasma partition coefficients of niraparib for total (Kp) and unbound (Kp,uu) drug levels Day 4 Intra-operative sample
Primary Phase 0 Arm B: Presence of Chromosomal fusion Presence of chromosomal fusion with the cutoff CT value of 35 in niraparib treated glioma tissue with IDH and ATRX loss. Day 4 Intra-operative sample
Primary Phase 0 Expansion Arm A: Progression-free survival in participants with demonstrated PK effects 6 month progression-free survival (PFS6) rate measured from the time of surgery to date of recurrence. 6 months
Primary Phase 0 Expansion Arm B: Progression-free survival in participants with demonstrated PD effects 6 month progression-free survival (PFS6) rate measured from the time of surgery to date of recurrence. 6 months
Secondary Drug-related toxicity Incidence of drug-related toxicity 24 months
Secondary Adverse events Number of adverse events through study completion, assessed up to 24 months. 24 months
Secondary Deaths Number and incidence of deaths 24 months
Secondary Incidence of clinical laboratory abnormalities per CTCAE Clinical laboratory abnormalities per CTCAE Up to 30 days after the last study dose
Secondary Overall survival Median overall survival 48 months
Secondary Phase 0 Arm A: Pharmacodynamics (PD) of niraparib Quantification of percentage of PAR positive cells with IHC assay or PAR concentration in tumor homogenates with an HT PARP pharmacodynamic assay II. Day 4 Intra-operative Tissue
Secondary Phase 0 Arm B: Pharmacokinetics (PK) of niraparib Total and unbound niraparib concentration in Gd-enhancing and non-enhancing tumor tissue Day 4 Intra-operative Tissue
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Terminated NCT02905643 - Discerning Pseudoprogression vs True Tumor Growth in GBMs

External Links